Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tetracyclic compound as plasma kallikrein inhibitor and application thereof

A compound and solvate technology, applied in the field of tetracyclic compounds, can solve the problems of poor physical and chemical properties of compounds, poor oral bioavailability, poor selectivity of related enzymes serine protease, etc., and achieve novel structure, high selectivity and good activity. Effect

Active Publication Date: 2021-06-22
CHENGDU KANGHONG PHARMA GRP
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the currently reported peptide and small molecule plasma kallikrein inhibitors have many limitations.
For example, icaratide has been reported to have the risk of causing allergic reactions
And most of the small-molecule plasma kallikrein inhibitors reported at present have highly polar and ionizable guanidino or amidino functional groups, which are considered difficult to pass through biomembranes and lead to very poor oral bioavailability (Tamie J. et al., ASP-634: An Oral Drug Candidate for Diabetic Macular Edema. ARVO Annual Meeting Abstract, March 2012, Volume 53, Issue 14)
Biocryst has developed an oral plasma kallikrein inhibitor BCX4161 (Dr.PhilCollis et al., BCX4161, An Oral Kallikrein Inhibitor: Safety and Pharmacokinetic Results Of a Phase1Study In Healthy Volunteers. Journal of Allergy and Clinical Immunology. Volume 133, Issue 2 , Supplement, 2014, AB39), the pharmacophore benzamidinyl group in its structure may lead to poor physical and chemical properties of the compound and thus affect the bioavailability of the drug, so it needs to be administered in a larger dose, and the clinical dosage reaches 400mg each time
In addition, existing plasma kallikrein inhibitors also suffer from poor selectivity to related enzymes such as KLK1, thrombin and other serine proteases
No small molecule plasma kallikrein inhibitors have been approved to date

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tetracyclic compound as plasma kallikrein inhibitor and application thereof
  • Tetracyclic compound as plasma kallikrein inhibitor and application thereof
  • Tetracyclic compound as plasma kallikrein inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0078] N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)-9-methoxy-12,13-dihydro-5H-imidazol[1,2-a]naphthalene[ 2,3-e][1,4]diazepine -2-Carboxamide

[0079]

[0080] Step a): Preparation of ethyl 2-amino-2-(hydroxyimino)acetate

[0081] Water (110 mL) was slowly added to ethyl cyanoformate (30.0 g, 0.303 mol), hydroxylamine hydrochloride (31.6 g, 0.455 mol) and sodium carbonate (80.3 g, 0.758 mol) in ethanol (200 mL) mixture, and the addition was completed , the reaction solution was stirred at 20°C for 10 h. After the reaction, the solvent was evaporated under reduced pressure, the residue was extracted with ethyl acetate (200 mL×3), the organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness under reduced pressure to obtain 2-Amino-2-(hydroxyimino) ethyl acetate, yield 65.0%, 1 HNMR (400MHz, DMSO-d 6)δ10.66-9.12 (m, 1H), 5.79-5.31 (m, 2H), 4.07-3.97 (m, 2H), 1.18-1.13 (m, 3H), ESI-MS (m / z): 133.2[ M+H] + . ...

Embodiment 2

[0103] N-((1-aminoisoquinolin-6-yl)methyl)-9-methoxy-12,13-dihydro-5H-imidazo[1,2-a]naphthalene[2,3-e] [1,4]diazepine - Preparation of 2-formamide

[0104]

[0105]The operation process is the same as in Example 1, except that 5-(aminomethyl)-4,6-dimethylpyridine-2-diamine dihydrochloride is used in step 1 with 6-(aminomethyl)isoquinoline-1 -Amine substitution, N-((1-aminoisoquinolin-6-yl)methyl)-9-methoxy-12,13-dihydro-5H-imidazo[1,2-a]naphthalene[2 ,3-e][1,4]diazepine -2-Carboxamide; ESI-MS(m / z): 465.3[M+H] + .

Embodiment 3

[0107] N-((1-amino-7-methoxyisoquinolin-6-yl)methyl)-9-methoxy-12,13-dihydro-5H-imidazo[1,2-a]naphthalene[ 2,3-e][1,4]diazepine - Preparation of 2-formamide

[0108]

[0109] The operation process is the same as in Example 1, except that 5-(aminomethyl)-4,6-dimethylpyridine-2-diamine dihydrochloride in step 1 is treated with 6-(aminomethyl)-methoxyiso Substitution of quinoline-1-amine gives N-((1-amino-7-methoxyisoquinolin-6-yl)methyl)-9-methoxy-12,13-dihydro-5H-imidazole [1,2-a]naphthalene[2,3-e][1,4]diazepine -2-Carboxamide; ESI-MS(m / z): 495.2[M+H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a tetracyclic plasma kallikrein inhibitor compound which is novel in structure, good in activity and high in selectivity, and can be widely applied to prevention or treatment of diseases related to plasma kallikrein activity.

Description

technical field [0001] The present invention relates to a tetracyclic compound with selective inhibitory activity on plasma kallikrein and its application. Background technique [0002] Plasma kallikrein (PK) is a member of the serine protease family and was first discovered in mammalian plasma. Encoded by a single gene (KLKB1) located on chromosome 4q35, it is mainly synthesized in the liver and abundantly present in the blood circulation in the form of plasma prokallikrein (PPK), which is further cleaved from its intrinsic Arg by coagulation factor XIIa -IIe key activation converted to PK. PK is a key enzyme of kallikrein-kinin system (KKS), which can act on high-molecular-weight kininogen (KH), thereby activating it to release small-molecule bradykinin (BK), and then acting on bradykinin Peptide receptors are involved in biological processes such as coagulation, fibrinolysis, complement activation, and inflammation. [0003] In recent years, with the in-depth research ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/04C07D471/14A61K31/5513A61P29/00A61P27/02A61P9/00A61P1/18A61P13/12A61P25/28A61P25/00A61P1/00A61P19/02A61P9/02A61P11/00A61P35/00A61P7/02A61P7/04A61P3/10A61P7/10
CPCC07D487/04C07D471/14A61P29/00A61P27/02A61P9/00A61P1/18A61P13/12A61P25/28A61P25/00A61P1/00A61P19/02A61P9/02A61P11/00A61P35/00A61P7/02A61P7/04A61P3/10A61P7/10
Inventor 吴红丽柯潇强晓明万剑飞
Owner CHENGDU KANGHONG PHARMA GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com